ALFA Finder
The call ran from 4:00 PM to 4:58 PM IST (58 min).
Key takeaways
Natco delivered a solid performance with diversified growth in Brazil and South Africa, successfully offsetting the expected decline in Revlimid revenue.
| Net Profit: guided vs achieved | 800.00% achieved Guided 700.00%–750.00%, 6.7% above the top of the range; confirmed by management |
|---|---|
| Management target | Revenue 15.0% FY28 |
| Revenue growth | ₹1019.4 Cr revenue, YoY decline due to lower Revlimid sales. |
|---|---|
| Margins | EBITDA margin at 30.4%, deemed sustainable by management. |
| Demand visibility | Strong traction in Brazil/Middle East; US remains a high-risk volume game. |
| Management confidence | Confident, shifting focus from 'lumpy' exclusivities to stable diversified base earnings. |
Growth
Strong international formulation growth led by a 66% jump in Brazil and steady base US business despite pricing pressure.
Outlook
Management raised PAT guidance to ₹775-800 Cr for FY27; FY28 target is 10-15% top-line growth.
Risks
Substantial price erosion in Pomalidomide due to multiple generic entrants and a 4-6 month delay in the agrochemical demerger.
Summary by ALFA Finder, written with AI assistance from the earnings call transcript the company filed, published . Open it on ALFA Filings ›
The results behind this call
Natco Pharma Q2 FY27 Results: Net Profit ₹202.6 Cr, Down 60.9% YoY
Natco Pharma Ltd reported revenue from operations of ₹967.3 Cr (-29.0% YoY) and net profit of ₹202.6 Cr (-60.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹202.6 Cr · -60.9% YoY
What management said last time
Full summary →From the call summary published .
Outlook they gave
FY25 PAT guidance maintained at ₹750Cr; ₹2000Cr fundraise planned for M&A.
Growth they described
Revenue fell to ₹794.4Cr from ₹1390.6Cr YoY; Brazil grew 180% to ₹178Cr.
Call details
| Company | Natco Pharma Ltd |
|---|---|
| NSE symbol | NATCOPHARM |
| ISIN | INE987B01026 |
| Call | Q2 FY27 earnings call |
| Date | Friday, 13 November 2026 |
| Time | 4:00 PM IST |
| Length | 58 min |
Natco Pharma Ltd: key numbers
- Share price
- ₹810.45
- Market cap
- ₹15,898 Cr
- Revenue (annual)
- ₹4,078 Cr
- Net profit (annual)
- ₹1,418 Cr
- P/E (TTM)
- 19.2×Sector 43.7×
- Promoter holding
- 46.22%-3.20% QoQ
- FII holding
- 15.37%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Other calls on Fri, 13 Nov
Today's concalls →
